公开(公告)号：EP1085848B1

公开(公告)日：2008-01-16

申请号：EP99930345.6

申请日：1999-06-18

申请人： SmithKline Beecham Corporation

发明人： CALLAHAN, James, F. ,  CHABOT-FLETCHER, Marie, C.

IPC分类号： A01N37/18

CPC分类号： A61K31/165 ,  C07C235/64

摘要： The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-λB, and methods for treating diseases in which activation of NF-λB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-λB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

公开(公告)号：EP1838311A1

公开(公告)日：2007-10-03

申请号：EP05821803.3

申请日：2005-12-23

申请人： Prosidion Limited

发明人： FYFE, Matthew Colin Thor, Prosidion Ltd ,  BERTRAM, Lisa, Sarah, Prosidion Ltd ,  THOMAS, Gerard Hugh, Prosidion Ltd ,  WILLIAMS, Geoffrey Martyn, Prosidion Ltd

IPC分类号： A61K31/44 ,  C07D401/12 ,  A61P3/04 ,  A61P3/10

CPC分类号： C07D213/83 ,  C07D213/32 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14

摘要： Compounds of formula (I), or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

公开(公告)号：EP1819704A1

公开(公告)日：2007-08-22

申请号：EP05815826.2

申请日：2005-12-02

申请人： Prosidion Limited

发明人： REPASI, Jozsef, Ubichem Research Ltd ,  SZABO, Andras, Ubichem Research Ltd

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P9/00

CPC分类号： C07D471/04

摘要： The present invention is directed to a novel form of a pyrrolopyridine-2-carboxylic acid amide of formula (I), which is an inhibitor of glycogen phosphorylase, compositions containing it and their use in therapy. The invention is also directed to processes for production of the novel form, novel intermediates used in said processes and processes for the production of said intermediates.

公开(公告)号：EP1819672A1

公开(公告)日：2007-08-22

申请号：EP05813607.8

申请日：2005-11-25

申请人： Prosidion Limited

发明人： BRADLEY, Stuart, Edward, Prosidion Limited ,  KRULLE, Thomas, Martin, Prosidion Limited ,  THOMAS, Gerard, Hugh, Prosidion Limited

IPC分类号： C07D209/30 ,  A61K31/404 ,  A61P3/10

CPC分类号： C07D405/12 ,  C07D209/42 ,  C07D401/12

摘要： Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐可用于预防或治疗糖尿病，高血糖症，高胆固醇血症，高胰岛素血症，高脂血症，高血压，动脉粥样硬化或组织缺血例如心血管疾病。 心肌缺血，并作为心脏保护剂。

公开(公告)号：EP1811902A2

公开(公告)日：2007-08-01

申请号：EP05825628.0

申请日：2005-11-15

申请人： (OSI) Eyetech, Inc.

发明人： SHIMA, David, T. ,  Ioannidou, Sofia ,  Robinson, Gregory S. ,  Xing, Heming

IPC分类号： A61B10/00 ,  G01N33/50

CPC分类号： G01N33/56966 ,  G01N33/5064 ,  G01N33/6803 ,  G01N33/6842

摘要： The invention relates to a plasma membrane marker for identifying fenestrae. The invention also relates to a method of visualizing fenestrae utilizing a plasma membrane marker and light microscopy. The invention also relates to a method of identifying a plasma membrane marker for fenestrae. In particular, the invention relates to the characterization of moesin as a component of fenestrae sieve plates. More particularly, the invention relates to the use of moesin as a plasma membrane marker. Moesin may be used as a plasma membrane marker for the identification of fenestrae or permeability of endothelial cells.

公开(公告)号：EP1776474A2

公开(公告)日：2007-04-25

申请号：EP05776987.9

申请日：2005-07-21

申请人： (OSI) EYETECH, INC.

发明人： SHIMA, David, T. ,  CALIA, Pericles ,  ROBINSON, Gregory, S. ,  WING, John, P. ,  MULLIN, Lori, M. ,  SMITH, Lillian, M. ,  SINANI, Ervin

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6837 ,  C12Q1/6816 ,  C12Q2561/125 ,  C12Q2561/101 ,  C12Q2525/205 ,  C12Q2533/107 ,  C12Q2537/125 ,  C12Q2531/113 ,  C12Q2525/155

摘要： The invention provides methods and compositions for detecting and/or quantifying modified nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic modified oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample.

公开(公告)号：EP1737497A2

公开(公告)日：2007-01-03

申请号：EP05778139.5

申请日：2005-04-13

申请人： (OSI) EYETECH, INC.

发明人： CALIAS, Pericles ,  COOK, Gary P. ,  SHIMA, David T. ,  ADAMIS, Anthony P. ,  NG, Yin-Shan ,  ROBINSON, Gregory S. ,  TURNER, David I. ,  GANLEY, Mary A.

IPC分类号： A61K47/48

CPC分类号： A61K49/0002 ,  A61K47/60 ,  A61K47/61

摘要： The invention provides compositions and methods for making and using sterically enhanced antagonist aptamer conjugates that include a nucleic acid sequence having a specific affinity for a target molecule and a soluble, high molecular weight steric group that augments or facilitates the inhibition of binding to, or interaction with, the target molecule binding partner by the target molecule when bound to the aptamer conjugate. The present invention also provides methods and formulations for ocular delivery of a biologically active molecule by attaching a charged moiety to the biologically active molecule and delivering the biologically active molecule by iontophoresis. Iontophoresis of a biologically active molecule that is conjugated to a high molecular weight neutral moiety, in enhanced by substituting the high molecular weight neutral moiety with a charged molecule of comparable size.

公开(公告)号：EP1027047B1

公开(公告)日：2006-10-04

申请号：EP98939213.9

申请日：1998-08-04

申请人： SMITHKLINE BEECHAM CORPORATION

发明人： GUDIPATI, Manga, R. ,  JUSHCHYSHYN, John, M. ,  PALEPU, Nageswara R. ,  VENKATESH, Gopadi, M.

IPC分类号： A61K31/415 ,  C07D233/02 ,  C07D233/04 ,  C07D409/06

CPC分类号： C07D409/06

摘要： This invention relates to (E)-α-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid arginyl charge-neutralization-complex, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

公开(公告)号：EP1398030B1

公开(公告)日：2006-09-06

申请号：EP03026947.6

申请日：1999-05-28

申请人： Prosidion Limited

发明人： Demuth, Hans-Ulrich ,  Glund, Konrad ,  Schlenzig, Dagmar ,  Kruber, Susanne

IPC分类号： A61K31/425 ,  A61K31/40

CPC分类号： C07D295/185 ,  A61K31/40 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61K45/06 ,  C07D277/04 ,  A61K2300/00

公开(公告)号：EP1675860A2

公开(公告)日：2006-07-05

申请号：EP04795392.2

申请日：2004-10-14

申请人： OSI Pharmaceuticals, Inc.

发明人： BECK, Patricia, Anne ,  CESARIO, Cara ,  COX, Matthew ,  DONG, Han-Qing ,  FOREMAN, Kenneth ,  MULVIHILL, Mark, Joseph ,  NIGRO, Anthony, Innocenzo ,  SAROGLOU, Lydia ,  STEINIG, Arno, G. ,  SUN, Yingchuan ,  WENG, Qinghua ,  WERNER, Douglas ,  WILKES, Robin ,  WILLIAMS, Jonathan

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.